Thor Medical ASA Logo

Thor Medical ASA

Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.

NANOV | OL

Overview

Corporate Details

ISIN(s):
NO0010597883 (+1 more)
LEI:
5967007LIEEXZXG6DK30
Country:
Norway
Address:
Drammensveien 167, 0277 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Thor Medical ASA is an emerging producer and supplier of radionuclides for medical use, specializing in alpha-particle emitters for targeted alpha therapies in oncology. The company has developed a proprietary technology for manufacturing these isotopes by separating naturally occurring radioactive decay products from thorium. This novel process eliminates the need for nuclear reactors or cyclotrons, providing a more efficient, cost-competitive, and environmentally sustainable alternative to traditional production methods.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 56.4 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 6.2 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 50.3 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 2.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228 - …
English 64.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228
English 7.7 KB
2025-08-01 08:58
Declaration of Voting Results & Voting Rights Announcements
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 46.1 KB
2025-08-01 08:58
Share Issue/Capital Change
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 2.0 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering - Attachment: Downlo…
Norwegian 59.1 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering
Norwegian 10.1 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
Norwegian 62.0 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
English 10.1 KB
2025-06-26 14:33
Director's Dealing
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 120.0 KB
2025-06-26 14:33
Major Shareholding Notification
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 51.7 KB
2025-06-26 14:33
Major Shareholding Notification
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 3.9 KB

Automate Your Workflow. Get a real-time feed of all Thor Medical ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Thor Medical ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Thor Medical ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.